| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.005 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.099 | 0.007 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |